Zanamivir , ≥98% , 139110-80-8

Synonym(s):
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid;4-Guanidino-Neu5Ac2en;Zanamivir

CAS NO.：139110-80-8

Empirical Formula: C12H20N4O7

Molecular Weight: 332.31

MDL number: MFCD03791324

EINECS: 691-117-1

PRODUCT Properties

• Melting point: 2560C (dec.)
• alpha: D20 +40.9° (c = 0.9 in water)
• Density: 1.75±0.1 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: H2O: soluble10mg/mL, clear
• pka: 3.82±0.70(Predicted)
• form: powder
• color: white to beige
• optical activity: [α]/D +30 to +40°, c = 1 in H2O
• Water Solubility: Soluble to 5 mM in water
• Stability: Hygroscopic
• InChIKey: ARAIBEBZBOPLMB-UFGQHTETSA-N

Description and Uses

Zanamivir was launched as Relenza in Australia for treatment of human influenza A and B virus infections. Zanamivir (4-guanidino-Neu5Ac2en) can be obtained by several similar ways, for instance in seven step synthesis starting from N-acetyI-D-neuraminic acid. Mechanistically, Zanamivir is a potent and specific inhibitor of neuraminidase (or sialidase), a key viral surface glycohydrolase essential for viral replication and disease progression by catalyzing the cleavage of terminal sialic acid residues from the glycoprotein. The in vitro activity of Zanamivir against a wide variety of influenza A and B strains was demonstrated in different model systems; its activity against clinically relevant isolates of influenza virus, with IC50 values ranging from 0.005 to 15 pM was superior to those of amantadine and rimantadine.

Influenza viral neuraminidase inhibitor; structural analog of the sialic acid. Antiviral

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P301+P312+P330-P305+P351+P338
• Hazard Codes: Xn
• Risk Statements: 22-36/37/38
• Safety Statements: 26
• WGK Germany: 3
• RTECS: RA9451000
• HS Code: 2932999000